The associated PROXIDRUGS partner Revvity launched a detection kit for quantifying the expression level of RNA-binding motif protein 39 (RBM39) in cell lysates. RBM39 is involved in transcriptional co-regulation and alternative RNA splicing and its suitability for this plate-based type of assay was identified within the ProxiDETECT project.
Upregulation of RBM39 indirectly participates in the growth and progression of tumors and its inhibition is lethal to several cancers including lung, breast and colorectal cancer. For these reasons, the RBM39 protein has become an emerging target for cancer diagnosis and treatment.
Comments